Larvol Delta - Aurigene-Oncology-Limited-Announces-Encouraging-Initial-Data-From-1ltsupgtstltsupgt-Two-Cohorts-of-Phase-1-Study-of-AUR112-an-Oral-Small-Molecule-Inhibitor-of-MALT1-in-RelapsedRefractory-Lymphoid-Malignancies

AUR-112 - Dr. Reddy’s

https://www.businesswire.com/news/home/20251201028387/en/Aurigene-Oncology-Limited-Announces-Encouraging-Initial-Data-From-1st-Two-Cohorts-of-Phase-1-Study-of-AUR112-an-Oral-Small-Molecule-Inhibitor-of-MALT1-in-RelapsedRefractory-Lymphoid-Malignancies

Dec 2, 2025

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next